The MBD1 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from the Raji B lymphocyte line, with targeted disruption of the MBD1 gene. These knockout cells provide a ready-to-use loss-of-function model for investigating the methyl-CpG binding domain protein 1 (MBD1) transcriptional repressor. The polyclonal format preserves genetic heterogeneity while effectively ablating MBD1 function, making the product ideal for pooled screening and epigenetic studies without requiring clonal isolation.
Raji cells are a human B lymphocyte line established from a Burkitt lymphoma patient, recapitulating key features of humoral immunity and B-cell malignancies. This host line is characterized by rapid proliferation and expression of B-cell surface markers, enabling investigations into oncogenic signaling and epigenetic dysregulation. Raji cells are extensively utilized to study DNA methylation dynamics, lymphomagenesis, and the impact of chromatin modifiers on B-cell biology. The line’s derivation from Burkitt lymphoma provides a clinically relevant context for examining B-cell tumor biology and therapeutic response.
MBD1 functions as a transcriptional repressor that specifically binds methylated CpG dinucleotides through its methyl-CpG binding domain. It recruits histone deacetylase complexes containing HDAC1 and HDAC2, leading to histone deacetylation, chromatin compaction, and gene silencing. Interacting partners such as MIZF and SETDB1 reinforce heterochromatin maintenance. Upstream, DNA methylation established by DNMTs and the SP1 transcription factor regulate MBD1 targeting, while downstream, MBD1 represses tumor suppressors like CDKN1A and CDH1. This mechanism couples DNA methylation to transcriptional repression, forming a critical axis in epigenetic gene regulation.
In B lymphocytes, MBD1-mediated silencing is essential for normal differentiation, and its dysregulation contributes to B-cell malignancies including Burkitt lymphoma. Aberrant MBD1 expression can enforce silencing of tumor suppressor genes, promoting proliferation and survival. The Raji knockout model permits dissection of MBD1-dependent contributions to oncogenic transcriptomes and testing whether its removal sensitizes cells to HDAC inhibitors or demethylating agents. This system is invaluable for linking epigenetic alterations to B-cell lymphoma pathology.
These polyclonal knockout cells support ChIP-qPCR for binding site analysis, bisulfite sequencing for methylation profiling, and RNA-seq for transcriptome characterization. They enable target validation studies, such as assessing reactivation of CDH1 after HDAC inhibition. Flow cytometry and proliferation assays further facilitate phenotypic evaluation. For additional technical details and ordering information, please contact Ascent Research.
